HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care through actionable cardiac insights, announced the appointment of Bryan Humbarger as chief commercial officer, effective Jan. 22, 2026. In the newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives, including the limited launch of the recently cleared HeartBeam System for arrhythmia assessment, heart attack detection indication and a 12-lead ECG extended wear patch monitor, while expanding outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption.
Humbarger brings extensive experience in commercializing medical devices, particularly in the cardiology space. His appointment signals HeartBeam's transition from a development-stage company to a commercial entity. The company's flagship product, the HeartBeam System, received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, as detailed in the company's Cleared Indications for Use.
The HeartBeam System is a cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing them into a standard 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, redefining cardiac health management.
The appointment comes at a critical time as HeartBeam prepares for the limited launch of its system. By focusing on cardiology partners and reference sites, the company aims to gather real-world evidence to support broader adoption. The success of this commercial strategy could position HeartBeam as a key player in the growing market for remote cardiac monitoring and diagnostics.
For more information about HeartBeam and its technology, visit the company's newsroom at https://ibn.fm/BEAT. The full press release is available at https://ibn.fm/9YzeT.
